Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer: Results from a Phase II Clinical Trial

C. Wu¹, L. Wu², X. Meng³, Y. Wang⁴, Q. Fan⁵, X. Wang⁶, K. Gu⁷, R. Ma⁸, C. Hu⁹, L. Lu¹⁰, F. Su¹¹, C. Yang¹², Z. Liu¹², J. Tian¹², X. Sun¹³, S. Sun¹⁴, Y. Cheng¹;

¹Internal Medicine, Jilin Cancer Hospital, Changchun, China, ²Chest medicine 2, Hunan Cancer Hospital, Changsha, China, ³Radiation Oncology, Shandong Cancer Hospital, Jinan, China, ⁴Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, ⁶Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ⁶Medical oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ⁶Medical oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ⁶Medical oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ¹⁰Medical oncology, Zhejiang Provincial People's Hospital, Hangzhou, China, ¹¹Medical oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁰Clinical Pharmaceutical Co., Ltd., Shandong, China, ¹¹Clinical Statistics, Shandong, China, ¹¹Clinical Statistics, Shandong, China, ¹⁰Clinical Statistics, Shandong, China,

BACKGROUND

 The combination of anti-PD-1/PD-L1 antibody and chemotherapy with or without anti-angiogenic agent has shown antitumor activity in non-small cell lung cancer (NSCLC).

 This study aims to assess the efficacy and safety of envafolimab (anti- PD-L1 antibody) in combination with suvemcitug (anti-VEGF antibody) and chemotherapy as second-line or later therapy in patients (pts) with advanced NSCLC.

METHODS

This was an open-label, multi-cohort, multicenter, phase II trial conducted in China.

 In Cohort C, NSCLC pts with at least one prior line of treatment were enrolled, stratified by the history of prior immunotherapy. Envafolimab (300 mg SC Q3W) plus suvementing (2 mg/kg IV Q3W) and docetaxel (75mg/m² IV Q3W) were administrated until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by investigator review using RECIST v1.1. Secondary endpoints included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR) and safety.

RESULTS

 As of June 30, 2023, 40 pts were enrolled in NSCLC cohort, including 20 immunotherapy (IO) treated NSCLC (Cohort C1) and 20 IO naïve NSCLC (Cohort C2). 72.5% (29/40) pts were treated with one prior therapy and 25.0% (10/40) pts with EGFR alteration.

Table1. Demographic and baseline characteristics

Demographic and baseline characteristics	C1 No.(%)	C2 No.(%)	Demographic and baseline characteristics	C1 No.(%)	C2 No.(%)
Age			EGFR mutation		
Mean (SD)	59.10 (5.79)	59.45 (9.03)	Yes	0	10 (50.00%)
Median (range)	59.00 (50, 72)	60.50 (43, 73)	No	16 (80.00%)	9 (45.00%)
Sex	10 (00 000)	10 (00 000)	Unknown	4 (20.00%)	1 (5.00%)
Male Female	18 (90.00%) 2 (10.00%)	16 (80.00%) 4 (20.00%)	Baseline ECOG PS		
Prior lines of therapy*			0	1 (5.00%)	2 (10.00%)
1 prior line	15 (75.00%)	14 (70.00%)	1	19 (95.00%)	18 (90.00%)
≥ 2 prior lines	5 (25.00%)	6 (30.00%)	Baseline SLD of target lesions(mm)		
Pathological classification			Mean (SD)	51.75 (23.54)	61.52 (45.76)
Adenocarcinoma	12 (60.00%)	19 (95.00%)		50.44	48.50
Squamous cell carcinoma	8 (40.00%)	1 (5.00%)	Median (range)		48.50 (14.00, 209.50)
PD-L1 expression ^{&}		Prior lines of therapy with 3rd generation			
IC < 1%	8 (40.00%)	12 (60.00%)	EGFR-TKI		
IC ≥ 1%	6 (30.00%)	2 (10.00%)	Yes	0 (0.00%)	9 (45.00%)#
Unknown	6 (30.00%)	6 (30.00%)	No	20 (100.00%)	11 (55.00%)

*: In cohort C1 means IO combined with chemotherapy, in cohort C2 means chemotherapy or TKI therapy;

&: Detected by SP263; #: One patient with EGFR mutation did not receive a 3rd generation EGFR-TKI therapy due to there was no T7900 mutation.


- For IO treated NSCLC (C1), 19 pts had at least one post treatment tumor assessment. The ORR and DCR were 26.3% (5/19) and 84.2% (16/19) respectively. The PFS was 6.6 (2.89-NE) months. 6 pts are still on treatment as of cut-off date.
- For IO naïve NSCLC (C2), 17 pts had at least one assessment, 3 pts achieved partial response and the DCR was 82.4% (14/17). The PFS was 8.2 (2,99-NE) months. 3 pts are still on treatment as of cut-off date.

Table2. Summary of the Overall Objective Response

	Cohort C1 N=19	Cohort C2 N=17
ORR , n (%)	5 (26.3%)	3 (17.6%)
95%CI	(9.15,51.20)	(3.80,43.43)
BoR , n (%)		
CR	1 (5.3%)	0
PR	4 (21.1%)	3 (17.6%)
SD	11 (57.9%)	11 (64.7%)
PD	3 (15.8%)	2 (11.8%)
NE	0	1 (5.9%)
DCR , n (%)	16 (84.2%)	14 (82.4%)
95%CI	(60.42,96.62)	(56.57,96.20)

ORR: Objective response rate; BoR: Best overall response; DCR: Disease control rate; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable.

Figure1. Kaplan-Meier curves of PFS in patients with NSCLC treated with suvemcitug plus envafolimab and docetaxel






Figure3. Duration of the Treatment

- In NSCLC pts,The most common treatment-related adverse events (TRAEs) were white blood cell count decreased (57.5%, 23/40), neutrophil count decreased (55.0%, 22/40), anaemia (37.5%,15/40), platelet count decreased (35.0%,14/40), asthenia (30.0%,12/40), alanine aminotransferase increased (22.5%,9/40), decreased appetite (22.5%, 9/40), alopecia (20.0%, 8/40), aspartate aminotransferase increased (15.0%,6/40), proteinuria (15.0%,6/40), gamma-glutamyltransferase increased (15.0%,6/40).
- The most common grade ≥ 3 TRAEs were neutrophil count decreased (52.5%, 21/40) and white blood cell count decreased (45.0%, 18/40).
- In total, 3 pts experienced TEAEs leading to death, one due to COVID-19, one due to acute myocardial infarction, and one due to Lung infection. All the three TEAEs were not related study treatment.

Table3. Overview of TEAEs

	N = 40 n (%)	N = 40 n (%)	
TEAEs	39 (97.5%)	AE leading to Death	3 (7.5%)
Related to study treatment	39 (97.5%)	Related to study treatment	0
Related to suvemcitug	36 (90.0%)	Related to suvemcitug	0
Related to envafolimab	34 (85.0%)	Related to envafolimab	0
Related to docetaxel	39 (97.5%)	Related to docetaxel Dose discontinuation	0 (25.0%)
TESAEs	24 (60.0%)	Suvemcitug	8 (20.0%)
Related to study treatment	19 (47.5%)	Envafolimab	4 (10.0%)
Related to suvemcitug	16 (40.0%)	Docetaxel	6 (15.0%)
Related to envafolimab	14 (35.0%)	Dose interruption	21 (52.5%)
Related to docetaxel	14 (35.0%)	Suvemcitug	15 (37.5%)
≥ Grade 3 TEAEs	30 (75.0%)	Envafolimab	16 (40.0%)
Related to study treatment	27 (67.5%)	Docetaxel	21 (52.5%)
Related to suvemcitug	14 (35.0%)	Dose reduction	8 (20.0%)
Related to envafolimab	16 (40.0%)	Suvemcitug Envafolimab	1 (2.5%)
Related to docetaxel	25 (62.5%)	Docetaxel	7 (17.5%)


Table4. Summary of TRAEs (≥15%)

TRAEs	Cohort C N=40		
TRAES	All grade	≥3 grade	
White blood cell count decreased	23 (57.5%)	18 (45.0%)	
Neutrophil count decreased	22 (55.0%)	21 (52.5%)	
Anaemia	15 (37.5%)	1 (2.5%)	
Platelet count decreased	14 (35.0%)	3 (7.5%)	
Asthenia	12 (30.0%)	2 (5.0%)	
Alanine aminotransferase increased	9 (22.5%)	2 (5.0%)	
Decreased appetite	9 (22.5%)	0	
Alopecia	8 (20.0%)	0	
Aspartate aminotransferase increased	6 (15.0%)	1 (2.5%)	
Proteinuria	6 (15.0%)	1 (2.5%)	
Gamma-glutamyltransferase increased	6 (15.0%)	0	

The pharmacokinetic exposure of envafolimab and suvemcitug in Cohort C was comparable with monotherapy.

Figure4.Pharmacokinetcis (PK): Cycle 1 serum concentrations (mean±SD) of Suvemcitug (A) and Envafolimab (B) in Cohort C1 and C2 safety cohort.

Figure 4A. Suvemcitug Figure 4B.Envafolimab



- This phase II clinical trial demonstrated antitumor activity and manageable safety profile of immunotherapy plus anti-angiogenic agent and chemotherapy in pts with NSCLC, who had failed at least one line of therapy.
- The addition of suvemcitug and envalolimab to docetaxel did not lead to significant worsening of TEAE.
- · We are exploring if any subgroup might be benefit from this regimen.
- Clinical trial information:NCT05148195.

Acknowledgment

We thank the patients and their families who made this trial possible and the clinical study teams involved in this trial. This study is sponsored by Shanghai Xianxiang Medical Technology Co., Ltd and 3D Medicines Inc.

Contact information

Ying Cheng, MD, 0431-80596003, il.cheng@163.com

Disclosure Dr. Cheng confirm that she does not have conflicts of interest to declare